EDGEWISE THERAPEUTICS ($EWTX) posted quarterly earnings results on Thursday, November 6th. The company reported earnings of -$0.39 per share, beating estimates of -$0.41 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $EWTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EDGEWISE THERAPEUTICS Insider Trading Activity
EDGEWISE THERAPEUTICS insiders have traded $EWTX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $EWTX stock by insiders over the last 6 months:
- ALAN J RUSSELL (Chief Scientific Officer) has made 0 purchases and 2 sales selling 101,907 shares for an estimated $1,485,299.
- KEVIN KOCH (President and CEO) sold 7,972 shares for an estimated $106,764
- JOANNE M. DONOVAN (CMO) sold 2,862 shares for an estimated $38,329
- BEHRAD DERAKHSHAN (Chief Business Officer) sold 2,491 shares for an estimated $33,360
- JOHN R MOORE (General Counsel) sold 2,098 shares for an estimated $28,097
- R MICHAEL CARRUTHERS (Chief Financial Officer) sold 1,428 shares for an estimated $19,124
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EDGEWISE THERAPEUTICS Hedge Fund Activity
We have seen 111 institutional investors add shares of EDGEWISE THERAPEUTICS stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRAIDWELL LP added 2,752,023 shares (+111.9%) to their portfolio in Q2 2025, for an estimated $36,079,021
- PERCEPTIVE ADVISORS LLC removed 1,907,379 shares (-29.1%) from their portfolio in Q2 2025, for an estimated $25,005,738
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,865,817 shares (-47.4%) from their portfolio in Q2 2025, for an estimated $24,460,860
- PARADIGM BIOCAPITAL ADVISORS LP added 1,747,788 shares (+39.8%) to their portfolio in Q2 2025, for an estimated $22,913,500
- SIREN, L.L.C. added 1,463,854 shares (+86.3%) to their portfolio in Q2 2025, for an estimated $19,191,125
- DEEP TRACK CAPITAL, LP removed 1,400,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $18,354,000
- BELLEVUE GROUP AG added 1,347,068 shares (+94.3%) to their portfolio in Q2 2025, for an estimated $17,660,061
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EDGEWISE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $EWTX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 08/19/2025
- RBC Capital issued a "Outperform" rating on 08/08/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/30/2025
To track analyst ratings and price targets for EDGEWISE THERAPEUTICS, check out Quiver Quantitative's $EWTX forecast page.
EDGEWISE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $EWTX recently. We have seen 4 analysts offer price targets for $EWTX in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Paul Choi from Goldman Sachs set a target price of $20.0 on 09/25/2025
- Tessa Romero from JP Morgan set a target price of $30.0 on 08/19/2025
- Leonid Timashev from RBC Capital set a target price of $49.0 on 08/08/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $42.0 on 06/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
